Sera Prognostics Inc. (NASDAQ:SERA), known as The Pregnancy Company, focuses on improving maternal and neonatal health through innovative pregnancy biomarker information. The company reported its earnings for the fourth quarter of 2025, with an EPS of -$0.16, better than the Zacks Consensus Estimate of -$0.17. Revenue was $10,000, falling short of expectations and down from $24,000 the prior year.
SERA's quarterly loss of $0.16 per share was better than the consensus estimate of a $0.17 loss, marking a +5.88% earnings surprise. This improved from the previous year's larger loss. In the prior quarter, SERA also beat expectations with a -$0.16 loss vs. anticipated -$0.19 (15.79% surprise).
However, revenue for the quarter ended December 2025 was $10,000, missing consensus by 75% and declining year-over-year. SERA has not met consensus revenue estimates in the last four quarters, reflecting ongoing commercialization challenges.
Despite financial headwinds, SERA achieved key milestones in 2025. The landmark PRIME Study, published in January 2026 in the peer-reviewed journal PREGNANCY (Society for Maternal-Fetal Medicine), showed that the PreTRM® Blood Test—tested in 5,018 women—significantly reduces the incidence of earliest preterm births and newborn complications.
Financially, SERA has a negative P/E ratio of approximately -3.3, indicating lack of profitability. The price-to-sales ratio is high (around 900+), reflecting investor expectations for future growth. However, SERA maintains minimal debt (debt-to-equity ~0.03) and a healthy current ratio of ~1.9, supporting liquidity for short-term obligations.
